A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety and Immune Activation of Adv-GM-CAIX Transduced Dendritic Cells in Patients with Metastatic Kidney Cancer

A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety and Immune Activation of Adv-GM-CAIX Transduced Dendritic Cells in Patients with Metastatic Kidney Cancer

kidneycancer

2 years
149 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
ALEXANDRA DRAKAKI, MD, PHD UNIVERSITY OF CALIFORNIA LOS ANGELES gives an overview of A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety and Immune Activation of Adv-GM-CAIX Transduced Dendritic Cells in Patients with Metastatic Kidney Cancer at the 2017 Kidney Cancer Association symposium in Miami, FL.

Up Next Autoplay